兽用/兽用疫苗市场（依动物种类、疫苗技术、给药途径、疾病类型及最终用户划分）－2025-2032年全球预测

预计到 2032 年，兽用/动物疫苗市场规模将达到 166.5 亿美元，复合年增长率为 7.15%。

关键市场统计数据
基准年2024年	95.8亿美元
预计年份：2025年	102.8亿美元
预测年份 2032	166.5亿美元
复合年增长率 (%)	7.15%

全面概述兽用疫苗市场格局，重点介绍关键驱动因素、相关人员的作用、技术进步以及影响策略的监管环境。

兽用疫苗领域正经历一场结构性变革，这场变革正在改变科学范式、商业策略以及生产者和服务供应商的企业发展方式。来自研究机构、临床机构、农业营运机构和监管机构的相关人员正围绕着一个通用目标汇聚：改善疾病控制、提升动物福利并建立更具韧性的供应链。随着科学基础扩展到先进的免疫学平台和数位健康工具，疫苗研发者和经销商的角色也从单纯的产品供应商转变为提供端到端预防和监测解决方案的综合合作伙伴。

此外，儘管监管制度在原则上日益趋于统一，但在实践中仍然存在差异，迫使企业制定兼顾本地合规性和全球扩充性的监管策略。同时，消费者和生产商对安全性、可追溯性和永续性的期望不断提高，这也提高了产品证据和生命週期透明度的要求。各组织必须优先考虑平台投资，促进跨产业伙伴关係，并调整商业模式以适应不断变化的终端用户行为。本导言从实证角度分析了技术进步、贸易动态和市场片段化如何相互作用，从而为兽用疫苗领域带来眼前的挑战和长远的机会。

突破性的科学突破、平台创新以及相关人员优先事项的转变，正在重新定义动物疫苗的研发、供应和应用。

过去十年间，动物健康领域发生了多项变革性转变，重塑了疫苗的发现、生产、交付和应用方式。其中一项关键的科学变革是平台技术的成熟，这些技术加速了抗原发现并实现了疫苗的模组化配置。这些平台缩短了研发週期，并有助于对新出现的病原体做出快速反应。同时，精准畜牧业和数位监测系统正在产生更高解析度的流行病学数据，从而形成反馈迴路，以前所未有的速度指导疫苗的设计和部署策略。

在商业性，人们越来越重视以价值为导向的提案，强调疾病预防、牛健康优化​​和综合服务交付的经济效益。策略性近岸外包、产能冗余和多元化的供应商网路正成为标准的风险缓解策略。监管方面的演变也显而易见，一些司法管辖区在保持严格的安全性和有效性标准的同时，为新型平台引入了简化的试验途径。这些转变的汇聚意味着，能够整合科学敏捷性、数据主导决策和稳健商业模式的组织将获得巨大的优势。因此，领导者必须协调研发重点、生产投资和相关人员参与，才能掌握这项结构性转变所带来的正面影响。

分析美国关税政策对2025年动物疫苗供应链、生产选择、定价及全球贸易格局的累积影响

2025年美国关税政策调整引入了复杂的贸易机制，对兽用疫苗产业的全球供应链和筹资策略产生了影响。累积效应导致疫苗生产所需的生物原料、特殊试剂和设备的进口投入成本上升，促使生产商重新评估筹资策略和成本转嫁方式。为此，许多公司争相寻找替代供应商，并考虑将生产基地迁至或扩大规模，以靠近需求中心，以减轻关税的影响。

这种转变也影响了与经销商和大型买家（例如经销商生产商和连锁兽医诊所）的商业价格谈判和合约结构。采购团队要求提高到岸成本和库存计画的透明度，这反过来又迫使製造商加强其供应链分析和情境规划能力。随着企业将采购转向关税更优惠的合作伙伴，贸易转移模式开始出现，但这种重组也带来了次要风险，包括更长的资质认证週期、供应商品质波动以及需要提交额外的监管文件。

从策略角度来看，关税环境加速了两个长期趋势：一是更重视策略性SKU的在地化生产经济效益；二是为关键投入品建构供应商冗余体系。先前已投资于灵活生产平台的企业发现，调整生产结构和维持供应连续性变得更加容易。展望未来，企业必须持续改善筹资策略，积极与贸易和监管相关人员沟通，并制定既能保障客户获得必要疫苗，又能应对未来潜在政策衝击的商业协议。

透过对动物种类、疫苗技术、给药途径、疾病类别和最终用户进行深度细分，挖掘针对性机会和风险。

按物种、平台、给药途径、疾病和最终用途进行细分，为将宏观趋势转化为目标策略提供了切实可行的视角。就动物类型而言，市场涵盖水产养殖、牛、伴侣动物、马、家禽和猪，其中伴侣动物又细分为猫狗。疫苗技术选择多样，包括结合疫苗、灭活疫苗、减毒活疫苗、重组疫苗、次单元疫苗和类毒素疫苗。给药途径——注射、鼻内和口服——影响疫苗的普及曲线和给药成本，而非侵入性给药途径则为大规模生产系统减轻劳动力负担提供了机会。

疾病类型细分（针对细菌、寄生虫和病毒）有助于研发优先排序和监测投资，因为病原体生物学和流行病学决定了彻底免疫和疾病缓解的可行性。最后，终端使用者细分（诊所、农场和兽医院，其中农场进一步细分为水产养殖、畜牧养殖、马匹养殖场、家禽养殖场和生猪养殖场）有助于明确分销管道和售后服务需求。例如，水产养殖和家禽养殖着重于大规模给药物流和给药技术，而诊所和兽医院则优先考虑伴侣动物品牌、安全性以及客户沟通工具。整合这些细分观点，企业可以设计出使产品属性与使用者支付意愿、营运限制和监管要求相符的产品组合策略，从而提高产品接受度和生命週期管理效率。

美洲、欧洲、中东和非洲以及亚太地区的区域动态和比较优势揭示了需求模式、製造地和法规环境。

区域动态影响企业在製造地、监管规划和市场策略方面的策略选择。在美洲，需求主要集中在伴侣动物照护和商业畜牧生物安全领域，这得益于成熟的经销网络和兽医服务系统。西欧对高端伴侣动物产品和先进的动物福利标准有着很高的需求，而其他地区则面临着监管能力和疾病流行程度的差异，因此需要采取适应性的註册和证据策略。在亚太地区，水产养殖业的快速成长以及家禽和猪肉生产的不断加强带来了巨大的机会，但企业必须应对不同的管理体制、当地的生产奖励，以及某些市场对本地化生产解决方案日益增长的偏好。

这些区域差异显示了不同的投资重点。以美洲为中心的策略强调品牌建立、以数据主导的诊所和兽医院价值提案以及整合的客户参与。欧洲、中东和非洲需要灵活的监管团队和量身定制的市场推广计划，而亚太地区则需要扩充性的生产方案、与当地公司伙伴关係以及对疾病监测进行投资，以反映该地区的疾病负担。将全球研发平台与特定区域的商业化策略结合的公司，更有可能在这三大区域实现更快的市场推广和更高的营运效率。

竞争格局以及主要企业和创新者的策略性倡议正在影响动物疫苗的伙伴关係、併购活动、产能投资和平台差异化。

兽用疫苗市场的竞争格局由规模和创新两大支柱所构成。历史悠久的兽用疫苗老字型大小企业在分销网络、监管专业知识和大规模生产能力方面保持优势，使其能够服务于包括大型农场和全球连锁兽医院在内的广泛终端用户群体。然而，规模较小的生技公司和平台创新者正日益崛起，它们率先开发重组构建体、载体疫苗和新型佐剂系统，从而提高疫苗的有效性、安全性和给药便利性。受託製造厂商（CDMO）发挥着重要作用，它们使现有企业和新参与企业都能在无需投入大量资金建设端到端生产设施的情况下扩大生产规模。

策略性倡议包括有针对性的併购以弥补能力缺口，合作开发伙伴关係以加速平台检验，以及授权协议以实现在地化生产并保护核心智慧财产权。优先考虑平台灵活性和模组化生产的公司能够快速调整抗原和物种，从而提升其应对需求波动的竞争优势。此外，投资于现场支援（例如低温运输解决方案、农场管理人员培训计划和数位监测工具）的公司可以透过减少实施摩擦来脱颖而出。总而言之，竞争格局正在从单一产品提案转向将科学差异化、卓越营运和以客户为中心的服务相结合的整合解决方案。

为产业领导者提供切实可行的策略建议，以充分利用技术、供应链韧性、监管参与和以客户为中心的商业化方法。

领导者应在技术、供应链、监管和商业等各个层面采取果断行动，将市场复杂性转化为竞争优势。优先投资于能够实现抗原敏捷且可扩展生产的平台技术，重点关注重组和模组化方法，以加快概念验证速度并快速应对不断变化的病原体情况。同时，应实现关键投入品供应商网路的多元化，并制定紧急时应对计画，包括合格的替代供应来源和灵活的生产方式，以应对地缘政治和关税方面的衝击。

我们将加强与监管机构的沟通，并调配资源以协调各重点区域的申报工作，并参与政策对话，为新型平台製定加速审批路径。在商业性，我们将调整市场区隔模型，使其与实际市场状况相符。我们将与诊所和兽医院建立合作关係，促进伴侣动物的领养，并为水产养殖、家禽养殖、畜牧养殖、马匹养殖和生猪养殖等农场设计大规模给药和给药解决方案。我们将利用数位化工具进行监控、上市后证据产生和客户支持，以建立信任并展现成功。最后，我们将寻求与契约製造、学术合作伙伴和当地市场领导者建立策略联盟，以在保持产品选择和快速上市的同时，平衡规模和创新。

一种严谨的调查方法，包括一手访谈、二手资讯、法规和专利分析、临床证据评估以及多源资料三角验证方法。

本分析所依据的研究整合了定性和定量数据，以确保其稳健性和实用性。主要研究包括对疫苗研发企业高管、生产企业领导者、监管专家以及大型终端用户（例如综合农业企业和多站点兽医诊所）进行结构化访谈。次要分析则依赖于同行评审文献、监管指导文件、临床试验註册信息、专利申请以及公司公开披露的信息，以验证趋势并检验有关技术成熟度和商业行为的论点。供应链映射和情境分析评估了贸易政策变化的影响，并分析了关税主导的采购转变的影响。

为确保资料完整性，我们交叉检验了多个独立资讯来源，并在专家研讨会上检验了各种假设。对于存在的资讯缺口，我们开展了有针对性的后续访谈，并与供应商进行了讨论，以澄清製造时间表、平台功能和区域法规等方面的细微差别。该调查方法兼顾了深度和透明度，使相关人员能够理解结论的依据及其对策略规划、风险管理和投资优先顺序的实际意义。

风险概述、策略机会及优先行动方案，旨在应对技术变革、贸易逆风和不断变化的终端用户期望。

总之，兽用疫苗产业正处于一个战略曲折点，科学创新、政策动态和不断变化的终端用户期望正在交汇融合，重塑竞争优势。抗原设计和平台灵活性的技术进步为伴侣动物、家畜和水产养殖的疾病控制开闢了新的途径，而贸易和关税压力则凸显了供应链韧性和适应性筹资策略的必要性。按动物类型、疫苗技术、给药途径、疾病目标和终端用户背景进行细分，可以为优先投资和定製商业化计划提供切实可行的框架。

那些能够开发平臺与营运弹性结合、投资于跨区域监管能力、并建立将科学差异化与生产规模结合的伙伴关係关係的管理者，将最有利于获取长期价值。那些拥有系统思维、能够整合监测、疫苗接种计划和上市后证据生成，从而为动物健康、生产者经济效益和公共卫生目标带来实际成果的组织，将占据有利地位。凭藉严谨的执行力和策略远见，相关人员可以将当前的挑战转化为可持续的竞争优势。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 扩大mRNA疫苗平台规模，以快速应对新出现的动物疾病
• 整合数位追踪技术，即时监测牲畜疫苗低温运输完整性
• 开发单剂量即可针对多种通用感染疾病的多效价疫苗
• 奈米颗粒佐剂系统在增强兽用疫苗免疫抗原性的应用日益广泛
• 为控製家禽地方病原体，自建疫苗生产设施的投资激增
• 为简化全球各兽医监管机构之间的疫苗核准，各方正努力协调监管措施。
• 重组病毒载体平台的进步提高了伴侣动物疫苗的安全性和有效性。
• 植物疫苗表现系统因其成本低廉且可规模化，正日益受到关注，尤其是在动物免疫方面。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依动物类型分類的兽药/兽用疫苗市场

• 水产养殖
• 牛
• 伴侣动物
  • 猫
  • 狗
• 马
• 家禽
• 猪

9. 依疫苗技术分類的兽用/兽用疫苗市场

• 结合疫苗
• 不活化疫苗
• 活病毒疫苗
• 重组
• 次单元
• 类毒素

第十章 依给药途径分類的兽用/兽用疫苗市场

• 注射
• 鼻腔
• 口服

第十一章 兽药/兽用疫苗市场（依疾病类型划分）

• 细菌
• 寄生虫
• 病毒性的

第十二章：兽药/兽用疫苗市场（依最终用户划分）

• 诊所
• 农场
  • 水产养殖场
  • 牛
  • 马术设施
  • 家禽养殖场
  • 养猪场
• 兽医诊所

第十三章：依地区分類的兽药/兽用疫苗市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 兽药/兽用疫苗市场（依类别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国兽药/兽用疫苗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Boehringer Ingelheim GmbH
  • Merck Animal Health
  • Zoetis Inc.
  • Hester Biosciences Limited
  • Indian Immunologicals Ltd.
  • Elanco Animal Health Incorporated
  • Ceva Sante Animale
  • Phibro Animal Health Corporation
  • Huvepharma
  • Arko Laboratories
  • Anicon Labor GmbH
  • Kemin Industries
  • Hipra
  • Vaxxinova
  • Pfizer, Inc.
  • Dechra Pharmaceuticals Limited
  • Bimeda Biologicals Inc
  • Neogen Corporation

The Veterinary/Animal Vaccines Market is projected to grow by USD 16.65 billion at a CAGR of 7.15% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 9.58 billion
Estimated Year [2025]	USD 10.28 billion
Forecast Year [2032]	USD 16.65 billion
CAGR (%)	7.15%

Comprehensive overview of the veterinary vaccines landscape revealing key drivers, stakeholder roles, technological progress, and regulatory interactions shaping strategies

The veterinary vaccines domain is in the midst of a structural transformation that is altering scientific paradigms, commercial strategies, and the operational footprints of manufacturers and service providers. Stakeholders across research institutions, clinical practice, farming operations, and regulatory bodies are converging around shared objectives: improved disease control, enhanced animal welfare, and resilient supply chains. As the scientific base expands to include advanced immunology platforms and digital health tools, the roles of vaccine developers and distributors are evolving from pure product suppliers to integrated partners offering end-to-end prevention and surveillance solutions.

Moreover, regulatory systems are increasingly harmonized in principle but remain heterogeneous in practice, prompting firms to design regulatory strategies that balance regional compliance with global scalability. Concurrently, consumer and producer expectations for safety, traceability, and sustainability are raising the bar for product evidence and lifecycle transparency. Taken together, these dynamics demand strategic clarity: organizations must prioritize platform investments, cultivate cross-sector partnerships, and align commercial models with shifting end-user behaviors. This introduction sets the stage for an evidence-driven exploration of how technological advances, trade dynamics, and market segmentation intersect to create both immediate challenges and durable opportunities in the veterinary vaccines landscape.

How transformative scientific breakthroughs, platform innovations, and shifting stakeholder priorities are redefining vaccine development, delivery, and adoption across species

The last decade has seen several transformative shifts that are recalibrating how vaccines are discovered, produced, delivered, and adopted across animal health sectors. A significant scientific shift is the maturation of platform technologies that accelerate antigen discovery and enable modular vaccine constructs; these platforms shorten development cycles and facilitate rapid responses to emergent pathogens. In parallel, precision livestock farming and digital surveillance systems are generating higher-resolution epidemiological data, creating feedback loops that inform vaccine design and deployment strategies more rapidly than before.

Commercially, there is a pronounced pivot toward value-based propositions that emphasize disease prevention economics, herd health optimization, and integrated service offerings-moving beyond transactional sales of products to subscription-style or outcome-oriented contracts. Supply chains are being redesigned for resilience: strategic nearshoring, capacity redundancy, and diversified supplier networks are becoming standard risk mitigants. Regulatory evolution is also notable, with some jurisdictions experimenting with streamlined pathways for novel platforms while maintaining rigorous safety and efficacy standards. These converging shifts mean that organizations able to integrate scientific agility, data-driven decision-making, and robust commercial models will gain disproportionate advantage. Consequently, leaders must align R&D priorities, manufacturing investments, and stakeholder engagement to capture the upside of these structural transitions.

Analyzing the cumulative effects of United States tariff policies in 2025 on supply chains, manufacturing choices, pricing dynamics, and global trade patterns for animal vaccines

United States tariff policy adjustments in 2025 introduced a layer of trade complexity that reverberated across global supply chains and procurement strategies in the animal health sector. The cumulative effect increased imported input costs for raw biological materials, specialized reagents, and equipment used in vaccine manufacturing, prompting manufacturers to reassess sourcing strategies and cost pass-through approaches. In response, many firms expedited qualification of alternative suppliers and evaluated relocation or expansion of manufacturing capacity closer to demand centers to mitigate tariff exposure.

These shifts also influenced commercial pricing negotiations and contract structures with distributors and large purchasers such as integrated producers and veterinary chains. Procurement teams sought greater transparency around landed costs and inventory planning, which in turn pushed manufacturers to strengthen supply chain analytics and scenario planning capabilities. Trade diversion patterns emerged as companies shifted procurement to tariff-favored partners, yet such reconfiguration created secondary risks including longer qualification timelines, variable supplier quality, and the need for additional regulatory filings.

From a strategic perspective, the tariff environment accelerated two durable trends: the economics of localized manufacturing for strategic SKUs and the emphasis on building supplier redundancy for critical inputs. Firms that had previously invested in flexible manufacturing platforms found it easier to adapt production mixes and maintain supply continuity. Looking ahead, organizations must continue to refine sourcing strategies, engage proactively with trade and regulatory stakeholders, and structure commercial agreements that recognize the potential for future policy shocks while preserving customer access to essential vaccines.

Deep segmentation insights across animal types, vaccine technologies, administration routes, disease categories, and end users to uncover targeted opportunities and risks

Segmentation offers a practical lens to translate macro trends into targeted strategies by species, platform, administration route, disease, and end-use context. When considering animal type, the market spans aquaculture, cattle, companion animals, equine, poultry, and swine with companion animals further dissected into cats and dogs-each subcategory exhibits distinct purchase drivers, dosing paradigms, and regulatory pathways that demand tailored commercialization approaches. On vaccine technology, choices range from conjugate, killed/inactivated, live attenuated, recombinant, subunit, to toxoid platforms; each technology carries trade-offs in manufacturing complexity, cold-chain demands, and differentiating claims, and therefore requires distinct pricing and evidentiary strategies. Route of administration-injectable, nasal, and oral-shapes adoption curves and administration cost profiles, with noninvasive routes presenting opportunities to lower labor burdens in mass production systems.

Disease type segmentation across bacterial, parasitic, and viral targets informs R&D prioritization and surveillance investments since pathogen biology and epidemiology dictate the feasibility of sterilizing immunity versus disease mitigation. Finally, end-user segmentation across clinics, farms, and veterinary hospitals-with farms further delineated into aquaculture farms, cattle farms, equine facilities, poultry farms, and swine farms-clarifies distribution channels and after-sales service needs; for example, aquaculture and poultry operations emphasize bulk dosing logistics and administration technologies, while clinics and veterinary hospitals prioritize companion animal brands, safety profiles, and client communication tools. Integrating these segmentation perspectives enables firms to design portfolio strategies that match product attributes with user willingness to pay, operational constraints, and regulatory requirements, thereby improving product uptake and lifecycle management.

Regional dynamics and comparative advantages across the Americas, Europe Middle East and Africa, and Asia-Pacific revealing demand patterns, manufacturing hubs, and regulatory climates

Regional dynamics materially shape strategic choices in manufacturing footprint, regulatory planning, and go-to-market approaches. In the Americas, demand is disproportionately weighted toward companion animal care and commercial livestock biosecurity, supported by established distribution networks and a mature veterinary services sector; the regulatory environment is characterized by well-developed pathways but significant expectations for clinical and safety data. In Europe, Middle East & Africa, heterogeneity is the primary challenge: Western Europe displays high demand for premium companion animal products and progressive animal welfare standards, while other subregions feature variable regulatory capacity and differing disease prevalence that call for adaptable registration and evidence strategies. In the Asia-Pacific region, rapid growth of aquaculture and intensification of poultry and swine production present large-scale opportunities, but companies must navigate diverse regulatory regimes, local manufacturing incentives, and a rising preference for locally produced solutions in some markets.

These regional contrasts suggest distinct investment priorities: Americas-focused strategies emphasize branding, data-driven value propositions for clinics and veterinary hospitals, and integrated customer engagement; Europe, Middle East & Africa requires flexible regulatory teams and tailored market-access plans; Asia-Pacific calls for scalable production options, partnerships with local players, and disease surveillance investments that reflect regional burden. Firms that harmonize global R&D platforms with region-specific commercialization playbooks will achieve faster adoption and higher operational efficiency across these three broad territories.

Competitive landscape and strategic moves by leading companies and innovators shaping partnerships, M&A activity, capacity investments, and platform differentiation in animal vaccines

Competitive dynamics in veterinary vaccines are characterized by a dual axis of scale and innovation. Established animal health companies retain advantages in distribution reach, regulatory expertise, and large-scale manufacturing capacity, enabling them to serve broad end-user bases such as major farming operations and global veterinary chains. However, smaller biotechnology firms and platform innovators are increasingly influential, pioneering recombinant constructs, vectored vaccines, and novel adjuvant systems that can improve efficacy, safety, and administration convenience. Contract development and manufacturing organizations (CDMOs) play an outsized role by enabling both incumbents and new entrants to scale production without the capital intensity of owning end-to-end facilities.

Strategic behaviors include targeted M&A to fill capability gaps, co-development partnerships to accelerate platform validation, and licensing arrangements that regionalize manufacturing while protecting core IP. Companies that emphasize platform flexibility and modular manufacturing gain the ability to pivot across antigens and species rapidly, creating competitive insulation against demand swings. Additionally, firms investing in field-level support-such as cold-chain solutions, training programs for on-farm administration, and digital monitoring tools-differentiate themselves by reducing adoption friction. In sum, the competitive battleground is shifting from single-product propositions to integrated solutions that combine scientific differentiation with operational excellence and customer-centric services.

Actionable strategic recommendations for industry leaders to capitalize on technology, supply chain resilience, regulatory engagement, and customer-centric commercialization approaches

Leaders should act decisively across technology, supply chain, regulatory, and commercial dimensions to convert market complexity into competitive advantage. Prioritize investment in platform technologies that enable antigen agility and scalable production, focusing on recombinant and modular approaches that reduce time to proof-of-concept and allow rapid response to shifting pathogen landscapes. Simultaneously, diversify supplier networks for critical inputs and develop contingency plans that include qualified alternate sources and flexible manufacturing arrangements to withstand geopolitical and tariff-related disruptions.

Strengthen regulatory engagement by allocating resources to harmonize dossiers across major territories and by participating in policy dialogues that shape accelerated pathways for novel platforms. Commercially, tailor go-to-market models to segmentation realities: cultivate relationships with clinics and veterinary hospitals for companion animal adoption, and design bulk dosing and administration solutions for farms, including aquaculture farms, poultry farms, cattle farms, equine facilities, and swine farms. Leverage digital tools for surveillance, post-market evidence generation, and customer support to build trust and demonstrate outcomes. Finally, pursue strategic collaborations with contract manufacturers, academic partners, and local market leaders to combine scale with innovation while preserving optionality and speed to market.

Rigorous research methodology describing primary interviews, secondary sources, regulatory and patent analysis, clinical evidence appraisal, and multi-source data triangulation approach

The research underpinning this analysis synthesized qualitative and quantitative inputs to ensure robustness and practical relevance. Primary research included structured interviews with senior executives across vaccine developers, manufacturing leaders, regulatory experts, and large end users such as integrated farming operations and multi-site veterinary practices. Secondary analysis drew on peer-reviewed literature, regulatory guidance documents, clinical trial registries, patent filings, and public corporate disclosures to triangulate trends and validate claims about technological readiness and commercial behavior. Supply chain mapping and scenario analysis were used to assess exposure to trade policy shifts and to evaluate the implications of tariff-driven sourcing pivots.

Data integrity was maintained through cross-validation across multiple independent sources and by testing alternative hypotheses during expert workshops. Where gaps existed, targeted follow-up interviews and vendor discussions were commissioned to ensure clarity on manufacturing timelines, platform capabilities, and regional regulatory nuances. The methodological approach balances depth and transparency, enabling stakeholders to understand both the evidence basis for conclusions and the practical implications for strategic planning, risk management, and investment prioritization.

Concluding synthesis of risks, strategic opportunities, and priority actions to navigate technological change, trade headwinds, and evolving end-user expectations in veterinary vaccines

In conclusion, the veterinary vaccines sector stands at a strategic inflection point where scientific innovation, policy dynamics, and evolving end-user expectations converge to reshape competitive advantage. Technological advances in antigen design and platform flexibility open new avenues for disease control across companion animals, livestock, and aquaculture, while trade and tariff pressures underscore the need for supply chain resilience and adaptive sourcing strategies. Segmentation across animal types, vaccine technologies, routes of administration, disease targets, and end-user contexts provides a pragmatic framework for prioritizing investments and customizing commercialization plans.

Executives who align R&D pipelines with operational agility, who invest in multi-regional regulatory competency, and who forge partnerships that combine scientific differentiation with manufacturing scale will be best positioned to capture long-term value. The pathways forward favor organizations that think systemically-integrating surveillance, vaccination programs, and post-market evidence generation-to deliver demonstrable outcomes for animal health, producer economics, and public health objectives. With disciplined execution and strategic foresight, stakeholders can convert current disruptions into durable competitive advantages.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Expansion of mRNA vaccine platforms for rapid response to emerging animal diseases
• 5.2. Integration of digital tracking technologies for real-time monitoring of vaccine cold chain integrity in livestock
• 5.3. Development of combined multivalent vaccines targeting multiple zoonotic pathogens in a single dose
• 5.4. Growing adoption of nanoparticle adjuvant systems to enhance immunogenicity in veterinary vaccines
• 5.5. Investment surge in autogenous vaccine production facilities for region-specific pathogen control in poultry
• 5.6. Regulatory harmonization efforts to streamline vaccine approval across different global veterinary authorities
• 5.7. Advances in recombinant viral vector platforms for improved safety and efficacy in companion animal vaccines
• 5.8. Increased focus on plant-based vaccine expression systems for cost reduction and scalable animal immunization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary/Animal Vaccines Market, by Animal Type

• 8.1. Aquaculture
• 8.2. Cattle
• 8.3. Companion Animals
  • 8.3.1. Cats
  • 8.3.2. Dogs
• 8.4. Equine
• 8.5. Poultry
• 8.6. Swine

9. Veterinary/Animal Vaccines Market, by Vaccine Technology

• 9.1. Conjugate
• 9.2. Killed/Inactivated
• 9.3. Live Attenuated
• 9.4. Recombinant
• 9.5. Subunit
• 9.6. Toxoid

10. Veterinary/Animal Vaccines Market, by Route Of Administration

• 10.1. Injectable
• 10.2. Nasal
• 10.3. Oral

11. Veterinary/Animal Vaccines Market, by Disease Type

• 11.1. Bacterial
• 11.2. Parasitic
• 11.3. Viral

12. Veterinary/Animal Vaccines Market, by End User

• 12.1. Clinics
• 12.2. Farms
  • 12.2.1. Aquaculture Farms
  • 12.2.2. Cattle Farms
  • 12.2.3. Equine Facilities
  • 12.2.4. Poultry Farms
  • 12.2.5. Swine Farms
• 12.3. Veterinary Hospitals

13. Veterinary/Animal Vaccines Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Veterinary/Animal Vaccines Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Veterinary/Animal Vaccines Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Boehringer Ingelheim GmbH
  • 16.3.2. Merck Animal Health
  • 16.3.3. Zoetis Inc.
  • 16.3.4. Hester Biosciences Limited
  • 16.3.5. Indian Immunologicals Ltd.
  • 16.3.6. Elanco Animal Health Incorporated
  • 16.3.7. Ceva Sante Animale
  • 16.3.8. Phibro Animal Health Corporation
  • 16.3.9. Huvepharma
  • 16.3.10. Arko Laboratories
  • 16.3.11. Anicon Labor GmbH
  • 16.3.12. Kemin Industries
  • 16.3.13. Hipra
  • 16.3.14. Vaxxinova
  • 16.3.15. Pfizer, Inc.
  • 16.3.16. Dechra Pharmaceuticals Limited
  • 16.3.17. Bimeda Biologicals Inc
  • 16.3.18. Neogen Corporation

LIST OF FIGURES

• FIGURE 1. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. VETERINARY/ANIMAL VACCINES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. VETERINARY/ANIMAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. VETERINARY/ANIMAL VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY KILLED/INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY KILLED/INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY KILLED/INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY KILLED/INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY KILLED/INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY KILLED/INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOXOID, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOXOID, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOXOID, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NASAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NASAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NASAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NASAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE FARMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE FARMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE FARMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE FARMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE FARMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE FARMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE FARMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE FARMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE FACILITIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY EQUINE FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY FARMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY FARMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY FARMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY FARMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE FARMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE FARMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE FARMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE FARMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 189. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 190. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 191. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 192. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 193. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
• TABLE 194. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
• TABLE 195. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 196. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 197. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 198. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 199. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 200. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 201. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 202. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 203. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2018-2024 (USD MILLION)
• TABLE 204. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2025-2032 (USD MILLION)
• TABLE 205. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 208. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 209. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
• TABLE 210. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
• TABLE 211. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 212. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 213. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 214. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 215. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 216. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 217. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 218. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 219. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2018-2024 (USD MILLION)
• TABLE 220. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2025-2032 (USD MILLION)
• TABLE 221. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 224. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 225. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
• TABLE 226. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
• TABLE 227. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 228. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 229. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 230. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 231. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 232. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 233. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 234. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 235. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2018-2024 (USD MILLION)
• TABLE 236. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2025-2032 (USD MILLION)
• TABLE 237. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 238. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2018-2024 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2025-2032 (USD MILLION)
• TABLE 253. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 254. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 255. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 256. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 257. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
• TABLE 258. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
• TABLE 259. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 260. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 261. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 262. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 263. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 264. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 265. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 266. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 267. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2018-2024 (USD MILLION)
• TABLE 268. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2025-2032 (USD MILLION)
• TABLE 269. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 270. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 271. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 272. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 273. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
• TABLE 274. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
• TABLE 275. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 276. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 277. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 278. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 279. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 280. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 281. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 282. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 283. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2018-2024 (USD MILLION)
• TABLE 284. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2025-2032 (USD MILLION)
• TABLE 285. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 286. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 287. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 288. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 289. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
• TABLE 290. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
• TABLE 291. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 292. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 293. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 294. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 295. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 296. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 297. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 298. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 299. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2018-2024 (USD MILLION)
• TABLE 300. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FARMS, 2025-2032 (USD MILLION)
• TABLE 301. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 302. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 303. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 304. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
• TABLE 305. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
• TABLE 306. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
• TABLE 307. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 308. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 309. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 310. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRAT